Buy APLS near 28.9 target 36.47 stop loss @ 28.82 Details The technical summary data tells us to buy APLS near 28.9 with an ...

Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price target decreased by Bank of America from $61.00 to $47.00 ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) – Research analysts at HC Wainwright reduced their FY2024 earnings ...

Republican state lawmakers are already poised to pass legislation that will allow for the prosecution of librarians.

Q3 2024 Earnings Call Transcript November 5, 2024 Apellis Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.46 EPS, expectations were $-0.32. Operator: Good morning, ladies ...

Oppenheimer analyst Francois Brisebois maintained a Buy rating on Apellis Pharmaceuticals (APLS – Research Report) today and set a price ...

In a report released today, Greg Harrison from Scotiabank maintained a Hold rating on Apellis Pharmaceuticals (APLS – Research Report), ...

Apellis Pharmaceuticals Inc (APLS) reports significant revenue growth but faces market and regulatory hurdles in Q3 2024.

Detailed price information for Apellis Pharmaceuticals Inc (APLS-Q) from The Globe and Mail including charting and trades.

Apellis Pharmaceuticals (APLS) delivered earnings and revenue surprises of -43.75% and 1.04%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the ...

Apellis Pharmaceuticals (APLS) stock falls as company's Q3 2024 financials disappoint with lower-than-expected U.S. sales ...